Dr. Austin Leigh Giunta Churchill, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 502 W Broad St Ste 1b, Falls Church, VA 22046 Phone: 703-894-2224 Fax: 315-800-5196 |
Laurie Susan Feinberg, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 3130 Fairview Park Dr, Suite 500, Falls Church, VA 22042 Phone: 703-269-6059 Fax: 703-269-5701 |
Jamie Mclaughlin, PTA Physical Medicine & Rehabilitation - Sports Medicine Medicare: Not Enrolled in Medicare Practice Location: 2841 Hartland Rd Ste 401b, Falls Church, VA 22043 Phone: 703-205-1233 Fax: 703-641-0189 |
Kellie Murphy, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 3300 Gallows Rd, Falls Church, VA 22042 Phone: 703-776-4001 |
News Archive
Vitro Diagnostics, Inc., dba Vitro Biopharma, announced the filing of a new United States patent application entitled "POU5-F1 Expression in Human Mesenchymal Stem Cells" and the development of new technology related to generation of human induced pluripotent stem cells (iPS).
The neuroscience company Cambridge Cognition Holdings PLC, which develops near patient technologies for the assessment of brain health, has announced results from a new technology feasibility study. The results demonstrate for the first time that consumer grade wearables such as the Apple Watch® and Microsoft Band can be used to accurately measure clinically relevant cognitive performance in everyday life using the Company's new Cognition Kit software.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented Protalix (NYSE-Amex: PLX), a leading biopharmaceutical company, in its licensing agreement with Pfizer Inc. to develop and commercialize a potential treatment for Gaucher's disease, a genetic disorder.
The second clinical trial involving stem cells from human embryonic cells has received the go-ahead. The news came from Advanced Cell Technology Inc. this Monday. The company announced that the U.S. Food and Drug Administration has cleared the way for its Phase I/II trial of retinal cells for patients with Stargardt's macular dystrophy, a childhood version of macular degeneration.
The Associated Press terms it a "symbol" of the "federal government's budget dysfunction" because physicians again are facing a steep cut in Medicare payments unless Congress intervenes. This time, though, such action will be considered in the context of other difficult budget questions.
› Verified 5 days ago